ASTRAZENECA PLC (AZN) Form 6-K — Sep 14, 2026
AstraZeneca announced on 14 September 2026 that its SERENA-4 Phase III trial of Etcamah (camizestrant) combined with palbociclib did not meet its primary endpoint of statistically significant improvement in progression-free survival in upfront first-line ER-positive, HER2-negative advanced breast cancer, although a numerical improvement was observed versus anastrozole plus palbociclib. The double-blind, randomised trial enrolled 1,371 patients newly diagnosed with stage IV de novo or recurrent disease, and the safety profile was consistent with the known profile of each medicine with no new safety concerns identified.
Key figures
- Safety
- consistent with known profile, no new safety concerns
- Trial outcome
- did not meet primary endpoint; numerical improvement observed
- Primary endpoint
- progression-free survival (PFS)
- Trial enrollment
- 1371
- Recommended dose mg
- 75
- Cambria program patients approx
- 10000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.